No cookies!

Cookies disabled. It’s not us, it’s your browser. Your Web browser must have cookies enabled for you to use all of the site’s functions.

MECHANISM
OF ACTIION

Lifitegrast blocks the interaction
of ICAM-1 and LFA-11

By binding to LFA-1, lifitegrast blocks the ICAM-1/LFA-1 interaction.1

In vitro studies demonstrated that lifitegrast may inhibit T-cell adhesion to ICAM-1 and the secretion of pro-inflammatory cytokines.1

The exact mechanism of action of lifitegrast in Dry Eye is not known.1

LET’S DIVE A LITTLE DEEPER INTO ICAM-1
  • ICAM-1 (intercellular adhesion molecule-1) may be overexpressed in the corneal and conjunctival tissues in Dry Eye Disease patients1
  • ICAM-1 binds to LFA-1, a receptor on the surface of T cells. This interaction can result in T-cell activation and migration to target tissues1

Important Safety Information

Contact lenses should be removed prior to the administration of Xiidra and may be reinserted 15 minutes following administration.

Want to learn more about Xiidra and Shire?

Tell us your e-mail address:

*First Name *Last Name
*CHOOSE AN OPTION

*All fields are required.

For US residents only.
All personal and/or medical information you have provided will be kept confidential and will not be used or distributed to anyone for any purpose other than what is explained in our privacy policy statement. We encourage you to read our privacy policy statement by clicking on this link: Review Shire privacy policy statement.

This consent will be in effect until such time as you opt out of the program.

NIICE Thanks for registering. We’re really looking forward to sending you updates.

Indication

Xiidra® (lifitegrast ophthalmic solution) 5% is indicated for the treatment of signs and symptoms of dry eye disease (DED).

Important Safety Information

In clinical trials, the most common adverse reactions reported in 5-25% of patients were instillation site irritation, dysgeusia and reduced visual acuity. Other adverse reactions reported in 1% to 5% of the patients were blurred vision, conjunctival hyperemia, eye irritation, headache, increased lacrimation, eye discharge, eye discomfort, eye pruritus and sinusitis.

To avoid the potential for eye injury or contamination of the solution, patients should not touch the tip of the single-use container to their eye or to any surface.

Contact lenses should be removed prior to the administration of Xiidra and may be reinserted 15 minutes following administration.

Safety and efficacy in pediatric patients below the age of 17 years have not been established.

Please click here for Full Prescribing Information.

Reference

  1. Xiidra [Prescribing Information]. Lexington, MA: Shire US.